Mangiferin, a novel nuclear factor kappa B-inducing kinase inhibitor, suppresses metastasis and tumor growth in a mouse metastatic melanoma model.

[1]  Masanobu Tsubaki,et al.  Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway. , 2016, International journal of oncology.

[2]  T. Takeda,et al.  Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase. , 2016, Chemico-biological interactions.

[3]  J. Dou,et al.  Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases. , 2015, American journal of translational research.

[4]  T. Takeda,et al.  Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model. , 2015, American journal of cancer research.

[5]  Masanobu Tsubaki,et al.  Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2. , 2015, American journal of translational research.

[6]  Zhen-hai Lu,et al.  Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway. , 2015, Cancer letters.

[7]  Duane D. Miller,et al.  Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties , 2015, PloS one.

[8]  J. Sheu,et al.  Hinokitiol, a tropolone derivative, inhibits mouse melanoma (B16-F10) cell migration and in vivo tumor formation. , 2015, European journal of pharmacology.

[9]  I. Nishigaki,et al.  Mangiferin in cancer chemoprevention and treatment: pharmacokinetics and molecular targets , 2015, Journal of receptor and signal transduction research.

[10]  T. Takeda,et al.  Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  S. Nomura,et al.  Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment , 2014, Pigment cell & melanoma research.

[12]  Mu-Kuan Chen,et al.  Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF‐κB and AP‐1 activity in human liver cancer cells , 2014, British journal of pharmacology.

[13]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[14]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[15]  Wei Cheng,et al.  Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. , 2013, Toxicology and applied pharmacology.

[16]  T. Takeda,et al.  Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines , 2013, Journal of experimental & clinical cancer research : CR.

[17]  E. Androphy,et al.  Chloroquine Promotes Apoptosis in Melanoma Cells by Inhibiting BH3 domain Mediated PUMA Degradation , 2013, The Journal of investigative dermatology.

[18]  M. Imano,et al.  Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. , 2012, Toxicology and applied pharmacology.

[19]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[20]  R. Splittgerber,et al.  NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway , 2011, Oncogene.

[21]  A. Taga,et al.  Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-κB in HL-60 cells , 2011, Archives of pharmacal research.

[22]  Q. Guo,et al.  Diallyl trisulphide‐induced apoptosis in human melanoma cells involves downregulation of Bcl‐2 and Bcl‐xL expression and activation of caspases , 2009, Clinical and experimental dermatology.

[23]  T. Satou,et al.  Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells , 2009, Cell biology international.

[24]  R. Sullivan,et al.  Molecular-targeted therapy in malignant melanoma , 2009, Expert review of anticancer therapy.

[25]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[26]  B. Aggarwal,et al.  Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. , 2008, Cancer research.

[27]  B. Aggarwal,et al.  Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalp , 2008, Blood.

[28]  Zhijian J. Chen.  Ubiquitin signalling in the NF-κB pathway , 2005, Nature Cell Biology.

[29]  P. Ramakrishnan,et al.  Receptor-Specific Signaling for Both the Alternative and the Canonical NF-κB Activation Pathways by NF-κB-Inducing Kinase , 2004 .

[30]  S. Verstovsek,et al.  Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies , 2004, Cancer.

[31]  M. Javadi,et al.  NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. , 2004, Biochemical and biophysical research communications.

[32]  Cheorl-Ho Kim,et al.  ERK1/2 mediates TNF‐α‐induced matrix metalloproteinase‐9 expression in human vascular smooth muscle cells via the regulation of NF‐κB and AP‐1: Involvement of the ras dependent pathway , 2004, Journal of cellular physiology.

[33]  G. Ghosh,et al.  Discreet mutations from c-Rel to v-Rel alter κB DNA recognition, IκBα binding, and dimerization: implications for v-Rel oncogenicity , 2004, Oncogene.

[34]  David J Newman,et al.  Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. , 2002, Current cancer drug targets.

[35]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[36]  Kenneth M. Yamada,et al.  Fibronectin, integrins, and growth control , 2001, Journal of cellular physiology.

[37]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Friedl,et al.  The biology of cell locomotion within three-dimensional extracellular matrix , 2000, Cellular and Molecular Life Sciences CMLS.

[39]  A. Newby,et al.  Synergistic upregulation of metalloproteinase‐9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF‐κB , 1998, FEBS letters.

[40]  M. Hartstein,et al.  The Role of the Integrin Family of Adhesion Molecules in the Development of Tumors Metastatic to the Orbit , 1997, Ophthalmic plastic and reconstructive surgery.

[41]  P. Ramakrishnan,et al.  Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. , 2004, Immunity.

[42]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[43]  J. Pezzuto,et al.  Plant-derived anticancer agents. , 1997, Biochemical pharmacology.